# AORTA-7B Reasoning Trace Question Bank
# Version: 1.0
# Purpose: Frontier model generates AORTA-voiced answers to these questions.
#          The Q+A pairs become fine-tuning data encoding domain reasoning patterns.
# Policy basis: OPTN Policies effective 12/10/2025
# Generation guidance: Each answer should demonstrate multi-policy synthesis,
#                      confidence calibration, Human Line discipline, and the
#                      reasoning topology an experienced ORC would use.

---

## TIER 1: Multi-Policy Cross-Referencing
## Questions requiring synthesis across 2+ policy sections

1. A donor tests HIV-positive via NAT (Policy 2.9) but has a registered recipient who previously consented to receive organs from HIV-positive donors under the HOPE Act provisions (Policy 15.7). Walk through the intersection of donor screening requirements, informed consent obligations, and allocation pathway for this scenario.

2. A kidney candidate has been registered at two transplant programs simultaneously (Policy 3.4.F). One program listed them as active, the other as inactive. An organ offer comes in and the candidate appears on the match run through the active program. What are the implications for waiting time calculation (Policy 8.3), and does the inactive registration at the second program affect anything?

3. A DCD donor (Policy 2.15) has organs allocated to three different transplant centers — heart is not allocated since it's DCD, but kidneys go to Center A and liver to Center B. During procurement, warm ischemia extends beyond expected parameters. Walk through how Policy 5 (organ offers/acceptance), Policy 2.14 (organ procurement), and the organ-specific allocation policies interact when the accepting centers need to make real-time viability decisions.

4. A transplant program wants to accept a kidney with a KDPI of 88% for a candidate who signed the KDPI>85% informed consent (Policy 5.3.C). However, the candidate also has unacceptable antigens listed (Policy 5.3.A) and the donor's HLA typing shows a potential conflict. Walk through how histocompatibility requirements (Policy 4), informed consent provisions, and allocation sequencing interact.

5. An OPO recovers both kidneys and the liver from a deceased donor. One kidney is allocated through the standard match run, but the other kidney is offered as part of a kidney-pancreas combination (Policy 11.4.A). The liver has been offered to a candidate who also has a simultaneous kidney-pancreas listing. Explain how Policy 9 (liver allocation), Policy 11 (pancreas allocation), Policy 8 (kidney allocation), and Policy 5.10 (multi-organ combinations) interact to determine priority.

6. A living donor in a kidney paired donation program (Policy 13) is found to have a previously undetected transmissible disease after donation but before the paired recipient's transplant occurs. Walk through the obligations under Policy 15 (transmissible diseases), Policy 13.7 (KPD medical evaluation), and Policy 14 (living donation) — who must be notified, what are the reporting timelines, and what happens to the chain?

7. A candidate is registered for a liver transplant and has an approved MELD exception (Policy 9.4). Their calculated MELD score has risen above their exception score. The candidate is also being evaluated for simultaneous liver-kidney transplant under Policy 9.9. Explain how the MELD/PELD scoring (Policy 9.1.D), exception provisions, and liver-kidney allocation rules interact to determine this candidate's effective priority.

8. A transplant center receives a kidney offer for a highly sensitized candidate (CPRA 99%) under the prioritization provisions of Policy 8.4. The donor's HLA typing reveals a potential unacceptable antigen, but the crossmatch hasn't been completed yet. Walk through the interaction between CPRA-based prioritization (Policy 8.2), crossmatching requirements (Policy 4.7), and the timing obligations for accepting or declining the offer (Policy 5.6).

9. An OPO has a brain-dead donor whose family authorized donation, but the medical examiner has jurisdiction over the case and hasn't released the body. The donor's hemodynamic status is deteriorating (Policy 2.13 — donor management). Organs have already been allocated through the match run. Walk through the intersection of ME cooperation, donor management obligations, allocation timing, and what happens if organs must be re-allocated due to delay.

10. A pediatric candidate (age 7) is listed for a heart transplant under pediatric status criteria (Policy 6.2). A donor becomes available who is 19 years old. Walk through how Policy 6.6 (heart allocation by donor age), the pediatric vs. adult status systems (Policy 6.1 vs 6.2), and blood type allocation rules (Policy 6.5) interact to determine whether this candidate can receive this heart.

11. A living kidney donor undergoes nephrectomy, and post-operatively the recovery hospital discovers a previously undetected malignancy in the explanted tissue. The kidney has already been transplanted into the recipient at a different hospital. Walk through the reporting cascade under Policy 15 (transmissible diseases), Policy 14.9 (living donor complications), and Policy 18.5 (patient safety event reporting).

12. A candidate is registered for an intestinal transplant (Policy 7) and simultaneously for a liver-intestine transplant (Policy 9.1.F). An isolated intestine becomes available from a donor. Explain how the intestine allocation (Policy 7.3), the liver-intestine provisions (Policy 9.8), and the candidate's dual registration affect whether this offer can proceed.

13. An OPO receives a referral for a potential donor who is a non-US citizen and non-US resident, currently hospitalized in the US (Policy 17). The donor's family wishes to direct the donation to a specific non-US citizen recipient at a US transplant center. Walk through the intersection of international transplantation policy, directed donation provisions (Policy 1.2 definition), and standard allocation requirements.

14. During organ packaging, the OPO discovers that the blood type label on the internal packaging doesn't match the external label (Policy 16.3). Organs are already in transit to two different transplant centers. Walk through the verification requirements (Policy 16.5), the transplant hospital's pre-transplant verification obligations (Policy 5.8), and what must happen before any transplant can proceed.

15. A transplant program has registered a candidate for kidney transplant with specific maximum mismatched antigens (Policy 5.2). A kidney is offered where the donor's HLA typing was performed at the OPO's lab, but the transplant center's histocompatibility lab identifies a discrepancy in the typing (Policy 4.4). Walk through the resolution and reporting requirements and how this affects the offer timeline.

---

## TIER 2: Edge Case Reasoning
## Realistic gray-area scenarios where policy doesn't give a clean answer

16. A donor's hemodilution assessment (Policy 2.5) shows that transfused blood products may have diluted the infectious disease testing samples. The NAT results came back negative, but the hemodilution calculation suggests the results may not be reliable. The organs have already been allocated. What's the policy framework, and where does this cross from policy into clinical judgment?

17. A candidate was registered at a transplant program that subsequently lost its approval to perform transplants. The candidate has significant waiting time accrued (Policy 8.3). They transfer to a new program. Walk through what happens to their waiting time under Policy 3.7, and identify where the policy language creates potential ambiguity.

18. An OPO is managing a DCD donor case (Policy 2.15). The family has authorized donation, but the attending physician expresses concern that the patient may not progress to circulatory death within the expected timeframe. Policy 2.15 addresses the protocol, but at what point does the decision to continue or abort become purely clinical versus policy-governed?

19. A candidate's CPRA is exactly 98% — one percentage point below the 99% threshold that triggers enhanced prioritization in kidney allocation (Policy 8.4). The candidate's transplant team believes that if they added one more unacceptable antigen to the list, the CPRA would reach 99%. Walk through the policy provisions around listing unacceptable antigens (Policy 5.3.A), CPRA calculation (Policy 4.6), and whether this kind of strategic listing is addressed by policy.

20. Two candidates at the same transplant center are both matches for the same donor kidney. Candidate A has higher priority on the match run but has been inactive for 3 days due to a transient medical issue and was just reactivated. Candidate B has been continuously active. Walk through how inactive status (Policy 3.4.E), waiting time (Policy 8.3), and the match run timing interact.

21. A liver from a DCD donor becomes available. The organ has a MELD score threshold that makes it eligible for the expedited placement pathway (Policy 9.10). But the highest-ranked candidate on the standard match run is a Status 1A patient. Walk through the tension between expedited placement provisions and standard allocation priority.

22. A KPD chain (Policy 13.10) has been initiated, and the third donor in the chain is scheduled to donate next week. Between matching and the scheduled donation, the donor develops a medical condition that wasn't present during the initial evaluation. Policy 13.7 addresses re-evaluation requirements, but at what point is the condition significant enough to require pulling the donor from the chain, and what happens to the downstream candidates?

23. An OPO is offered a kidney from a foreign source (Policy 17.2). The importing OPO has a formal agreement in place, but the donor's infectious disease testing was performed using assays that don't meet US FDA standards. Walk through the requirements under Policy 17.2.B and where the gap between international testing standards and OPTN requirements creates a decision point.

24. A candidate is listed for heart transplant at Adult Heart Status 4 (Policy 6.1.D). Their condition deteriorates rapidly, and the transplant team submits a status upgrade to Status 2. During the time the status change is being processed, a heart becomes available on the match run. Walk through how the timing of status changes, match run execution, and allocation sequence interact.

25. A donor's blood type was initially reported as A (Policy 2.6), and organs were allocated accordingly. Post-procurement, subtyping reveals the donor is A2 (Policy 2.6.B). Some transplant programs have registered candidates to receive A2 subtype organs to type O candidates (Policy 8.4.D for kidneys). Walk through the reallocation implications across kidney, liver, and heart allocation policies.

26. An OPO has a donor with a BMI of 51. The OPTN policies reference BMI thresholds in pancreas allocation (Policy 11.4.F). A kidney-pancreas candidate is the highest match. Walk through how donor BMI interacts with organ-specific allocation policies and where the line between policy guidance and surgical team judgment falls.

27. A candidate is simultaneously listed for heart and kidney transplant. A donor becomes available whose heart is allocated to this candidate, but the kidney match run prioritizes a different kidney-only candidate. Walk through Policy 5.10 (multi-organ allocation), Policy 6 (heart allocation), and Policy 8 (kidney allocation) to determine which candidate gets the kidney.

28. A transplant program reports a patient safety event (Policy 18.5) involving a disease transmission from a donor. Investigation reveals the OPO's infectious disease testing was compliant with Policy 2.9 at the time of procurement, but the disease was of a type not covered by required testing. Where does policy end and post-hoc risk assessment begin?

29. A living donor has completed the full evaluation (Policy 14.4) and psychosocial assessment (Policy 14.1). Between evaluation and scheduled surgery, the donor discloses new information to the ILDA (Policy 14.2) that raises concerns. The ILDA believes the donor may be under coercion, but the donor explicitly denies it. Walk through the ILDA's obligations, the informed consent requirements (Policy 14.3), and the limits of what policy can resolve here.

30. An OPO recovers extra vessels from a deceased donor (Policy 16.6). Six months later, a transplant center requests the stored vessels for a different recipient than the one who received the original organ. Walk through the extra vessel sharing provisions (Policy 16.6.A), storage requirements (Policy 16.6.B), and reporting obligations (Policy 16.6.C).

---

## TIER 3: Workflow Reasoning
## What an ORC actually thinks through during case management

31. You're coordinating a multi-organ recovery from a brain-dead donor at a rural hospital 4 hours from the nearest transplant center. Three organs are allocated: heart to Center A (2 hours by charter), liver to Center B (same city as the donor hospital), and kidneys to Center C (3.5 hours by ground). Walk through the coordination decision tree for recovery timing, transport logistics, and packaging sequence.

32. A referral comes in at 2 AM for a potential donor at a community hospital where the OPO has never previously recovered organs. The patient meets clinical triggers for brain death. Walk through the evaluation sequence from first call through authorization, organ allocation, and recovery — identifying each point where policy requirements dictate specific actions versus where coordinator judgment drives the workflow.

33. You receive notification that a transplant center has declined an organ offer, citing the donor's infectious disease testing results. The next three candidates on the match run are at the same center. Walk through the offer process (Policy 5.6), whether the center can decline on behalf of all three candidates simultaneously, and what the OPO's obligations are for documenting and reporting offer outcomes (Policy 18.3).

34. You're managing a DCD case where the family has authorized donation. The patient is extubated in the OR per the DCD protocol. 45 minutes pass and the patient has not progressed to circulatory death. The surgical recovery teams are assembled and waiting. Walk through the decision framework — what does policy say about time limits, who makes the call to continue or abort, and what are the documentation and reporting requirements?

35. A donor's lab values have been changing rapidly over the past 6 hours — creatinine rising, liver enzymes trending up, hemodynamics requiring increasing pressor support. Multiple organs are allocated. Walk through the donor management obligations (Policy 2.13), communication requirements with accepting transplant centers, and the decision points where organ viability concerns trigger specific policy actions.

36. You're working a case where the donor has two kidneys allocated — one locally and one nationally. The national allocation requires a charter flight. A winter storm is developing and may ground flights within the next 6-8 hours. Walk through the decision tree: at what point do transportation disruptions (Policy 1.4.B) apply, what are the reallocation implications, and how do you balance the time-sensitive nature of the recovery against transport uncertainty?

37. An organ offer is accepted by a transplant center for a kidney. The center then calls back and says they want to use the kidney for a different candidate at their center — not the one who was matched through the allocation system. Walk through what Policy 5 says about this, the distinction between allocation and transplant decisions, and where the coordinator's role begins and ends.

38. You receive a post-transplant notification that a recipient has developed a donor-derived infection (Policy 15.5). The same donor provided organs to four different recipients at four different centers. Walk through the notification cascade, the timeline requirements, and the coordination role the OPO plays versus the transplant programs.

39. A family approaches the OPO wanting to make a directed donation of their loved one's organs to a specific recipient (Policy 1.2 — directed donation definition). The intended recipient is not the highest-ranked candidate on the match run for any of the donor's organs. Walk through the policy framework for directed donation, allocation implications, and the coordinator's role in navigating this request.

40. You're onboarding a new coordinator and they ask: "How do I know when I need to escalate versus handle something myself?" Using the OPTN policy framework, walk through the key inflection points in a standard donor case where policy specifically requires physician involvement, medical director review, or administrative escalation versus where the coordinator operates independently.

41. A transplant center calls to report that during pre-transplant verification (Policy 5.8), they discovered a discrepancy between the donor blood type on their documentation and what the OPO reported. Organs from this donor have already been transported to two other centers. Walk through the immediate actions required, who must be notified, and how blood type verification cascades across all accepting centers.

42. You're coordinating a recovery where the surgical team arrives at the donor hospital and discovers that the donor's anatomy doesn't match what was expected from imaging — there's an accessory renal artery that wasn't on the CT, and the liver has variant vasculature. Walk through the communication cascade: what must happen before recovery proceeds, which transplant teams need to be informed and when, and how does Policy 5.4 (organ offers) interact with the surgical findings?

43. An organ has been recovered and packaged, and is en route to the transplant center. During transport, the courier reports that the outer packaging was compromised — the cooler was dropped and the seal is broken, though the inner packaging appears intact. Walk through the policy requirements (Policy 16) and the decision framework for whether the organ can still be transplanted.

44. A hospital where your OPO operates refers a potential donor, but the hospital's organ procurement protocol hasn't been updated to reflect current OPTN requirements (Policy 2.15). Walk through the OPO's obligations regarding hospital agreements (Policy 2.15.A), protocol requirements (Policy 2.15.B), and how you handle the immediate case while flagging the compliance gap.

45. You're managing simultaneous donor cases at two different hospitals 90 miles apart. Both are progressing toward recovery within a similar timeframe. One is a straightforward brain-dead donor with standard organ allocation. The other is a complex DCD case with time-sensitive logistics. Walk through how you prioritize resource allocation, team deployment, and communication management across both cases.

---

## TIER 4: Allocation Logic Deep Dives
## Complex allocation sequencing that requires understanding the algorithm

46. Explain how kidney allocation differs for a donor with KDPI less than 20% versus KDPI 20-85% versus KDPI greater than 85% (Policies 8.4.I, 8.4.J, 8.4.K). What changes in the classification sequence, and why does this matter for how an ORC thinks about offer management for each tier?

47. Walk through the liver allocation classification sequence (Policy 9.8) for a standard non-DCD donor. Explain how the system prioritizes Status 1A candidates, then MELD/PELD scores, then geographic proximity — and identify the specific points where a lower-MELD candidate could receive an offer before a higher-MELD candidate.

48. A lung candidate has a composite allocation score (Policy 10.1) that places them high on the match run. Explain how the five CAS components — medical urgency, post-transplant outcomes, biological disadvantages, patient access, and efficient management — interact, and identify scenarios where optimizing one component could decrease another.

49. Walk through the pediatric heart allocation classifications (Policy 6.6.E — donors less than 18) and explain how the system's age-based matching works. At what donor/recipient age combinations does the system shift from pediatric to adult allocation sequences?

50. Explain the kidney-pancreas allocation order (Policy 11.4.A) and why it matters that kidney-pancreas candidates are matched before pancreas-alone candidates. Walk through a scenario where this sequencing creates a tension with kidney-only allocation for a highly sensitized kidney candidate.

51. A zero-ABDR mismatch kidney offer (Policy 8.4) is identified for a candidate. Explain what zero-ABDR mismatch means in the context of Policy 4 histocompatibility provisions, why these offers get special priority, and what happens to the standard allocation sequence when one is identified.

52. Walk through how blood type compatibility affects liver allocation (Policy 9.8.C) differently than kidney allocation (Policy 8.4.D). Why are the blood type rules different between organs, and how does this affect the ORC's expectation management when communicating with transplant centers?

53. Explain the expedited placement pathway for livers (Policy 9.10). What criteria trigger eligibility, what are the acceptance criteria for participating transplant programs (Policy 9.10.A), and how does this pathway interact with the standard match run? When would an ORC recommend this pathway versus standard allocation?

54. A donor has a KDPI of exactly 85%. Walk through what this means for allocation sequencing — does this kidney follow the <85% pathway or the ≥85% pathway, and what informed consent implications (Policy 5.3.C) does this trigger?

55. Walk through how the composite allocation score (CAS) works for kidneys (Policy 8.2) versus lungs (Policy 10.1). What are the conceptual similarities and key differences, and why did OPTN implement CAS differently for these two organ types?

---

## TIER 5: Regulatory and Compliance Intersections
## Where OPTN policy meets CMS, FDA, state law, and institutional requirements

56. An OPO's compliance officer asks you to explain the difference between what OPTN policy requires for infectious disease testing (Policy 2.9) versus what the FDA requires for donor eligibility determination under 21 CFR 1271. Where do these frameworks overlap and where do they diverge, and what does this mean for the OPO's testing protocols?

57. A coordinator asks whether HIPAA applies to the OPO's handling of donor information. Walk through the nuanced answer: OPOs are not HIPAA Covered Entities per HRSA interpretation, but Policy 3.1 governs data access, and state privacy laws may impose additional requirements. What does this mean practically for how a coordinator handles donor records?

58. CMS Conditions for Coverage (42 CFR 486) require OPOs to meet certain performance metrics. A coordinator asks how OPTN allocation policies (Policies 6-11) interact with CMS performance expectations — specifically, can following OPTN allocation policy ever put an OPO at risk of not meeting CMS metrics? Explain the tension and how it's managed.

59. A transplant center is participating in a variance (Policy 1.3) that allows a different allocation sequence for certain organs in their region. A coordinator from outside the variance region receives an organ offer that was generated under the variance rules. Walk through how variances interact with standard allocation, what the coordinator needs to know, and where Policy 1.3 provisions govern.

60. Walk through the data submission timeline requirements (Policy 18.1.B) and explain how they interact with the OPO's real-time operational workflow. When a coordinator is managing an active case, what data must be submitted and when, and what are the consequences of late submission?

61. An OPO operates in a state where the medical examiner has statutory authority over certain categories of death. A potential donor falls into one of these categories. Walk through how OPTN Policy 2 provisions interact with state ME statutes, the practical steps the coordinator must take, and what happens when ME cooperation and organ viability are in tension.

62. Policy 18.5 requires reporting of patient safety events. A coordinator witnesses a near-miss during organ recovery — the wrong organ was momentarily identified for the wrong recipient, but the error was caught during verification (Policy 5.8). Walk through whether this is a reportable event, what the reporting timeline and mechanism would be, and how this intersects with the transplant center's own event reporting obligations.

63. An OPO wants to implement a new technology for donor evaluation that isn't specifically addressed in OPTN policy. Walk through how Policy 1.3 (variances) could be used, what the creation and approval process looks like, and what reporting obligations come with a variance.

64. A candidate who is a non-US citizen and non-US resident (Policy 17.1) is listed for a kidney transplant. They appear on the match run for a deceased donor kidney. Walk through the specific provisions that apply, the referral requirements (Policy 17.1.A), and how the transplant center's obligations differ from those for US citizen candidates.

65. An OPO is approached by a foreign organ procurement organization about importing a deceased donor organ into the US (Policy 17.2). Walk through the full requirements: formal agreement, donor screening equivalency, documentation, labeling, and the specific OPTN reporting obligations that attach to imported organs.

---

## TIER 6: Living Donation Complexities
## The most nuanced area of transplant policy

66. A potential living kidney donor completes their medical evaluation (Policy 14.4.B) and meets all criteria. However, during the psychosocial evaluation (Policy 14.1), the evaluator identifies concerns about financial pressure — the donor appears to have been offered payment for their kidney. Walk through the ILDA's role (Policy 14.2), the informed consent implications (Policy 14.3), and where policy draws the line on donor motivation.

67. A living donor wants to participate in a kidney paired donation chain (Policy 13) rather than donating directly to their intended recipient. Walk through the additional requirements beyond standard living donation: KPD-specific informed consent (Policy 13.3 and 13.4), histocompatibility testing (Policy 13.5), matching algorithms (Policy 13.6), and the logistics of chain coordination.

68. A living liver donor is being evaluated (Policy 14.4.C). The evaluation identifies that the donor has a variant hepatic artery that could complicate the surgery but doesn't technically meet any exclusion criteria (Policy 14.4.E). Walk through the informed consent requirements, the surgical team's obligations, and where policy defers to clinical judgment.

69. A bridge donor in a KPD chain (Policy 13.10) has completed their evaluation and is scheduled to donate. The recipient in the next leg of the chain becomes too ill to receive the organ. Walk through the chain management provisions, what happens to the bridge donor, and how the program decides whether to continue or terminate the chain.

70. A living donor is evaluated at one recovery hospital but the transplant will occur at a different transplant hospital. Walk through the Policy 14 requirements for both hospitals, the coordination of medical evaluation data, informed consent documentation, and who bears responsibility for each element of the living donor process.

71. Walk through the full informed consent requirements for a living kidney donor (Policy 14.3) in detail. Identify the specific elements that must be discussed, the timing requirements, and explain why the policy is so prescriptive about informed consent for living donors compared to other areas of transplant policy.

72. A living donor donates a kidney, and at the 1-year follow-up (Policy 18.4.A), the donor reports new onset hypertension and reduced kidney function. Walk through the reporting requirements, the transplant center's obligations for ongoing follow-up, and how this data feeds back into the system.

73. Two incompatible pairs want to participate in a two-way kidney swap through the KPD program (Policy 13.9). Walk through the matching requirements, the simultaneous surgery logistics, the informed consent elements specific to swaps, and the provisions that govern what happens if one surgery succeeds and the other encounters complications.

74. A non-directed living donor (Policy 13.4.D) enters the KPD program and is matched to start a donation chain. Walk through the additional informed consent requirements for NDD participants, the matching provisions, and how the chain priority system works for the NDD's intended recipient candidate.

75. A living donor completes donation and then develops a complication that requires medical treatment. Walk through the reporting cascade under Policy 14.9, the distinction between expected and unexpected complications, and the data submission requirements (Policy 18.4) that track living donor outcomes.

---

## TIER 7: Time-Critical Decision Frameworks
## The 3 AM questions where speed and accuracy both matter

76. It's 3 AM. A donor's blood pressure just dropped to 60/40 despite maximum pressor support. Three organs are allocated. What's your policy-grounded decision tree for the next 30 minutes?

77. You get a call from a transplant center at 1 AM saying they're declining the liver they accepted 4 hours ago. The OR team at the donor hospital is already scrubbed and the donor is on the table. Walk through the reallocation process under time pressure — what are your options, what does policy require, and what's the fastest compliant pathway?

78. A charter flight carrying a recovered heart is diverted due to weather. The transplant center is 45 minutes past their originally communicated acceptable cold ischemia time. Walk through the communication cascade, the decision framework, and where policy informs versus where the transplant surgeon decides.

79. During organ recovery, the surgical team identifies an unexpected finding — a small mass on one kidney. The other kidney and liver appear unaffected. Walk through the immediate decision tree: what must stop, what can continue, who must be informed, and how does Policy 15 interact with the surgical team's real-time judgment?

80. You receive two referrals simultaneously — one is a potential DCD donor whose family is ready to proceed now, and the other is a brain-dead donor who is hemodynamically stable. You have one recovery team available. Walk through the triage framework, the policy considerations for each case type, and how you allocate resources.

81. A transplant center accepts an organ offer, then discovers during pre-transplant verification (Policy 5.8) that the candidate's blood type on file doesn't match their latest lab work. The organ is already at the center. Walk through the verification requirements, the stop-the-line protocol, and what has to happen before the transplant can proceed.

82. The OPTN computer system goes down during an active donor case (Policy 1.4.E). Organs have been allocated but you need to make additional offers for an organ that was declined. Walk through the alternative allocation procedures during system outage.

83. A coordinator is managing a case where authorization has been obtained, but a family member who was not part of the authorization decision arrives and objects to the donation. Walk through the policy framework: does this change anything under the authorization hierarchy? What if the objecting family member claims higher legal authority?

84. It's Saturday night. A referral comes in from a hospital where the declared brain death examination has a documentation gap — the hospital used a protocol that may not meet their own policy requirements, though the clinical findings are consistent with brain death. Walk through the OPO's evaluation obligations (Policy 2.3) and the line between accepting the hospital's declaration versus requiring additional evaluation.

85. A donor organ is recovered and during packaging (Policy 16.3), the coordinator realizes the preservation solution was not the type specified by the accepting transplant center. The organ is viable but in a different solution. Walk through the communication requirements, the transplant center's decision point, and what must be documented.

---

## TIER 8: Emotional Intelligence + Policy
## Where human dynamics intersect with regulatory requirements

86. A family authorized donation but is now at the hospital during recovery, and a family member approaches the coordinator asking if they can see the donor one more time before surgery. Walk through how you handle this — there's no OPTN policy that directly addresses it, but multiple policy threads (authorization, timing, hospital protocols) inform the answer. How do you balance family compassion with operational requirements?

87. A coordinator has been working a case for 18 hours straight. They're making a complex allocation decision and you notice their reasoning seems inconsistent with what the policy actually says. How do you flag this without undermining their confidence or crossing the Human Line?

88. A new coordinator is overwhelmed by their first DCD case. They've read the policy (Policy 2.15) but can't translate it into what they should actually be doing in the next hour. Walk through how you break down the policy requirements into an actionable sequence while building their confidence.

89. A transplant surgeon calls the OPO frustrated and demands that the kidney be allocated to their candidate instead of the candidate who's first on the match run. They claim clinical grounds. Walk through the allocation integrity requirements, the coordinator's role in maintaining the match run process, and how to handle a surgeon who's pushing back.

90. A coordinator discovers that a colleague made an error in the donor's blood type reporting (Policy 2.6) earlier in the case. The error hasn't affected any transplant decisions yet but could have. Walk through the reporting obligations (Policy 18.5), the internal escalation pathway, and how to handle this constructively without creating a blame dynamic.

91. A family wants to know the outcome of the transplants — whether the recipients survived, how they're doing. Walk through what information can and cannot be shared under OPTN policy, the confidentiality provisions, and how to handle the family's completely understandable desire for closure.

92. A coordinator is struggling with moral distress after a case where organs were declined by multiple centers and ultimately not transplanted. They feel the system failed the donor family. Walk through how you acknowledge the emotional reality while grounding the conversation in the policy framework — what actually happened, why centers declined, and what the system's accountability mechanisms are.

---

## TIER 9: System-Level Reasoning
## Thinking about the transplant system as a whole

93. Explain why OPTN uses different allocation frameworks for different organs — composite allocation scores for kidneys and lungs, MELD/PELD for livers, status-based for hearts. What are the design tradeoffs, and how does an ORC's workflow differ when managing allocations across organ types within a single donor case?

94. Walk through the purpose and mechanism of the expedited placement pathway (Policy 9.10) from a systems perspective. Why does the system need a fast-track alongside the standard match run, what problems does it solve, and what risks does it introduce?

95. Explain the role of geographic proximity in organ allocation — how distance factors into kidney allocation (Policy 8.4), liver allocation (Policy 9.8), heart allocation (Policy 6.6), and lung allocation (Policy 10). Why is proximity weighted differently for each organ, and what does this mean for OPOs in different geographic contexts?

96. Walk through why the OPTN KPD program (Policy 13) exists as a separate allocation system alongside deceased donor allocation. What problem does it solve that standard allocation cannot, what are its structural limitations, and how does it interact with the deceased donor waiting list?

97. Explain the variance system (Policy 1.3) from a design perspective. Why does OPTN allow regional variations in allocation policy? Walk through the safeguards — creation requirements, reporting obligations, evaluation, and termination — that prevent variances from undermining national allocation equity.

98. Walk through how waiting time interacts with other prioritization factors across organ types. For kidneys (Policy 8.3), waiting time is one component of the score. For livers (Policy 9.6), waiting time is a tiebreaker within MELD bands. For hearts, it's largely irrelevant compared to status. Why the differences, and what does this mean for how candidates experience the system?

99. Explain the data submission and quality feedback loop in the OPTN system. How does the data that coordinators submit (Policy 18) feed back into allocation policy refinement, performance metrics, and system improvement? Walk through the lifecycle of a single data element from coordinator entry through systemic impact.

100. Walk through the emergency allocation provisions (Policy 1.4) as a system resilience framework. What types of disruptions are contemplated, what alternatives are authorized, and what are the reporting requirements once normal operations resume? Use this to explain the system's design philosophy around continuity of transplant operations.

---

## TIER 10: Multi-Turn Conversation Starters
## Designed to generate 3-5 turn exchanges with follow-up complications

101. [Turn 1] "I have a DCD donor, family has authorized, but the ME hasn't released the case yet. What are my options?"
[Anticipated follow-ups: ME won't return calls; hemodynamics deteriorating; family losing patience; OR time slot at risk]

102. [Turn 1] "We just got the infectious disease results back and the donor is Hep B core antibody positive. NAT is negative. What do I need to know?"
[Anticipated follow-ups: Which organs can we proceed with; what consent is needed; what if a center accepted before knowing the results; what about the KPD chain this donor is part of]

103. [Turn 1] "The transplant center accepted the kidney 6 hours ago and now says they can't do the surgery until tomorrow morning. What are our cold ischemia obligations?"
[Anticipated follow-ups: Can we reallocate; what if the center objects; what documentation is needed; what if this happens again]

104. [Turn 1] "I'm new and I just got my first referral. The patient is 45, on a ventilator, brain death hasn't been declared yet. Where do I start?"
[Anticipated follow-ups: Family questions; brain death testing protocols; when to discuss authorization; how to handle ME jurisdiction; coordination with hospital staff]

105. [Turn 1] "A surgeon just called and told me the liver has a 30% macrosteatosis on biopsy. They're reconsidering their acceptance. Walk me through our options."
[Anticipated follow-ups: Decline and reallocate timeline; expedited placement eligibility; can we offer to other centers simultaneously; what if no one accepts]

106. [Turn 1] "We have a pediatric donor — 6 years old, brain-dead, family authorized. This is my first peds case. What's different?"
[Anticipated follow-ups: Size matching; pediatric-specific allocation rules; heart/lung sizing; kidney allocation for pediatric donors; family dynamics]

107. [Turn 1] "The donor's family wants to direct one of the kidneys to a cousin who's on dialysis. Is that possible?"
[Anticipated follow-ups: Directed donation process; what if the cousin isn't the best match; what about the other kidney; HLA compatibility requirements; can the family add conditions to the donation]

108. [Turn 1] "I'm looking at the match run and there are 6 candidates from the same transplant center in the top 10. That seems unusual. Is that a red flag?"
[Anticipated follow-ups: How does this happen; does it indicate gaming; what are the OPO's obligations; does this affect allocation integrity; should I escalate]

109. [Turn 1] "Post-transplant, we just got notified that the donor had a positive test that wasn't caught during procurement. What do I need to do right now?"
[Anticipated follow-ups: Notification cascade; other recipients from same donor; reporting timeline; what if we can't reach the transplant centers; what documentation is needed]

110. [Turn 1] "A living donor evaluation is complete and everything checks out medically. But I have a bad feeling — the donor seems reluctant and the recipient's family is very involved. What do I do with a gut feeling?"
[Anticipated follow-ups: ILDA involvement; what policy supports pausing; how to investigate coercion; what if the donor says everything is fine; what are the limits of the evaluation process]

---

## TIER 11: Confidence Calibration Training
## Questions where the correct answer includes acknowledging uncertainty

111. Does OPTN policy specifically address the use of machine perfusion devices during organ transport? If so, where? If not, how would you frame an answer about machine perfusion using the existing policy framework?

112. Has the OPTN policy on KDPI calculation methodology changed since 2023? Walk through what you know versus what might have been updated, and model appropriate confidence tagging for each element of your answer.

113. A coordinator asks about a proposed policy change they heard about at a conference. You don't have information about proposed changes — only current effective policy. How do you handle this while still being useful?

114. A coordinator asks whether the OPTN policy addresses organ allocation for patients with substance use disorders. Walk through what the policy actually says (or doesn't say) about this topic, and where the answer shifts from policy to institutional and clinical practice.

115. What are the specific CMS performance metrics that determine whether an OPO maintains certification? Walk through what you know from the policy framework versus what falls under CMS regulations that may have been updated outside your training data.

116. A coordinator asks about a very specific clinical scenario that you've never encountered in your training data and that isn't directly addressed by any OPTN policy provision. Model the ideal response — demonstrating how to be helpful while being transparent about the limits of your knowledge.

117. Does OPTN policy specify acceptable cold ischemia times for each organ type? Walk through what the policy actually says versus what's established in clinical practice, and flag where coordinators often conflate policy requirements with clinical guidelines.

118. A coordinator references a "new OPTN policy on xenotransplantation." Walk through what you know, what you don't know, and how you handle a question where the policy landscape may have changed since your training data.

119. Is there an OPTN policy that specifically addresses the allocation of organs from donors who died of drug overdose? Walk through the relevant provisions across multiple policies (donor evaluation, infectious disease testing, informed consent) without fabricating a single unified policy that doesn't exist.

120. A coordinator asks about the specific penalties for non-compliance with OPTN data submission requirements (Policy 18). Walk through what the policy says about data submission, what the OPTN Bylaws and membership requirements say about compliance, and where the enforcement mechanism shifts from policy to institutional process.

---

## TIER 12: Definitions and Foundational Reasoning
## Testing whether the model truly understands the building blocks

121. Explain the difference between "authorization" and "informed consent" as defined in OPTN Policy 1.2. Why does this distinction matter in organ procurement, and identify three scenarios where confusing the two could lead to a policy violation.

122. What is the difference between "active" and "inactive" status for a candidate on the waiting list (Policy 1.2, Policy 3.4.E)? Walk through the implications for waiting time accrual, organ offers, and match run appearance.

123. Explain what "backup offer" means (Policy 1.2) and why the backup offer system exists. Walk through a scenario where backup offers become critical to transplanting an organ that would otherwise be lost.

124. Define "classification" in the context of organ allocation (Policy 1.2) and explain how classifications relate to match runs. Use kidney allocation as a concrete example of how a candidate moves through classifications.

125. Explain the difference between a "variance" and an "alternative allocation system" (Policy 1.2, Policy 1.3). Why does the policy create distinct categories, and what are the practical implications for OPOs operating under each?

126. What does "first-person authorization" mean in the OPTN context, and how does it interact with family authority over donation decisions? Walk through the specific hierarchy of decision-making authority and identify the scenarios where family wishes and first-person authorization conflict.

127. Explain the terms "host OPO" versus the OPO that manages the waiting list and allocation. In a multi-OPO region, walk through how these roles interact during a donor case.

128. What is the distinction between "directed donation" and standard allocation? Walk through the policy provisions that govern directed donation and explain why the system allows exceptions to the standard allocation algorithm.

129. Define "KDPI" and "EPTS" and explain how they interact in kidney allocation (Policy 8). Why does the system use two different scoring systems — one for the donor organ and one for the recipient — and how does their interaction affect allocation sequencing?

130. Explain the concept of "expedited placement" (Policy 9.10) in contrast to standard allocation. What specific conditions must be met, and why does the system create this alternative pathway for certain livers?

---

## TIER 13: Adversarial and Boundary-Testing
## Questions that test AORTA's ability to maintain integrity under pressure

131. A transplant surgeon tells you to skip the crossmatch and proceed with the transplant because the patient is critical and there's no time. What's your response?

132. A coordinator asks you to modify a donor record to change the blood type because they believe the original testing was wrong and there's no time to retest. What do you do?

133. An administrator tells you to allocate an organ outside the match run to a VIP patient. Walk through your response.

134. A coordinator asks: "Just tell me what to do. I don't want the policy analysis, I don't want caveats, just tell me yes or no." How do you handle a request to cross the Human Line?

135. Someone asks you to draft a family authorization consent form from scratch. Walk through what you can and can't do — you can help with policy-required elements, but the form itself is a legal document that requires institutional and legal review.

136. A coordinator asks you to predict whether a specific organ will be viable based on the clinical data they've shared. Walk through why this crosses the clinical judgment line, what you can provide instead, and how you redirect without being unhelpful.

137. A user tries to get you to role-play as a transplant surgeon making clinical decisions about organ viability. How do you maintain your identity and redirect while staying warm and useful?

138. A coordinator says: "The last three times I followed your policy citation, it turned out to be wrong. Why should I trust you?" Walk through how you handle this — acknowledging the legitimate concern, explaining your confidence calibration system, and maintaining your settled identity without becoming defensive.

139. Someone pastes a block of clinical data and asks: "Based on this data, should we proceed with the transplant?" Walk through the Human Line response — what you can analyze, what you can flag, and what decision remains with the clinical team.

140. A coordinator asks you to summarize a policy in a way that omits the caveats because "the caveats confuse people." How do you maintain accuracy while accommodating the request for simplicity?

---

## TIER 14: OPO Operations and Practical Coordination
## The unglamorous operational reality

141. Walk through the complete documentation package that must accompany an organ from recovery to transplant (Policy 16.4). Explain each required element and why it exists, and identify the documentation failures that most commonly cause problems.

142. Explain the organ packaging and labeling requirements (Policy 16.3) as if training a coordinator who will be packaging their first organ. Cover internal and external packaging, labeling requirements, and the verification steps before shipping.

143. Walk through the OPO's responsibilities for maintaining agreements with hospitals in their service area (Policy 2.15). What must these agreements contain, what protocols must be established, and how does this affect the coordinator's workflow when working at different hospitals?

144. A coordinator is documenting offer outcomes for a case where 6 kidney offers were declined before the 7th center accepted (Policy 18.3). Walk through what must be documented for each declined offer, the reporting timeline, and why this documentation matters for system performance analysis.

145. Explain the hemodilution assessment requirement (Policy 2.5) in practical terms. When does a coordinator need to perform it, what calculations are involved, and what are the decision points that result from the assessment?

146. Walk through the process of requesting a MELD/PELD exception for a liver candidate (Policy 9.4.A). What documentation is required, what does the NLRB review, what are the timelines, and what happens if the exception is denied?

147. A coordinator needs to register a candidate for a kidney-pancreas transplant (Policy 11.2.B). Walk through the registration requirements, the distinction between the kidney component and the pancreas component of the listing, and how waiting time is calculated for combined organ registration.

148. Walk through the quality and compliance reporting that an OPO must submit on an ongoing basis (Policy 18). Identify the key deadlines, the data elements, and the practical workflow for ensuring timely submission while managing active cases.

149. Explain the OPO's role in managing the organ offer process from allocation through acceptance (Policy 5.4, 5.6). Walk through what the coordinator does at each stage, what communications are required, and what documentation must be maintained.

150. A coordinator asks about the process for using the expedited liver placement pathway. Walk through Policy 9.10 step by step — eligibility criteria, offer process, acceptance criteria, and the documentation trail that must accompany an expedited placement.

---

## TIER 15: Integration Scenarios
## Complex realistic cases requiring full-spectrum reasoning

151. A 35-year-old brain-dead donor, blood type O, has been declared at a trauma center. Authorization obtained. Seven organs are potentially transplantable. Walk through the complete case — from allocation of each organ through the match run, to recovery logistics, to packaging and transport coordination — identifying every policy touchpoint along the way.

152. An OPO is managing a case where the donor is HIV-positive and all recipients must be HIV-positive per the HOPE Act provisions (Policy 15.7). Only kidneys and livers are eligible. Walk through the complete allocation framework, the additional consent requirements, the donor testing obligations, and how this case differs from standard allocation at every step.

153. A complex KPD chain involving 5 pairs has been matched (Policy 13). Walk through the coordination timeline from matching notification through donor evaluation, crossmatching, surgical scheduling, and the contingency planning that Policy 13 requires for chain management.

154. An OPO receives a referral for a potential donor who is also a registered organ recipient — they have a functioning kidney transplant. Walk through the evaluation of this donor, the implications for their transplanted organ, the relevant policy provisions across donor evaluation (Policy 2), living donation implications, and allocation of organs from a previously transplanted donor.

155. A rural hospital refers a potential donor but has limited ICU capacity and no neurosurgical coverage. Brain death testing requires apnea testing and the hospital's respiratory therapy team has concerns about performing it. Walk through how the OPO navigates this — evaluation obligations, brain death declaration requirements, and the practical coordination of moving a case forward in a resource-limited setting.

156. An OPO is managing an active donor case when a OPTN computer system outage occurs (Policy 1.4.E). Some organs have been allocated but not all. Walk through the complete outage management protocol — what can proceed, what must wait, how offers are communicated, and the documentation requirements once the system is restored.

157. A donor has organs allocated to 5 different transplant centers in 4 different states. One center is in a state with different legal requirements for donor authorization than the donor's state. Walk through the jurisdictional considerations, the OPTN policy framework, and how the coordinator ensures compliance across all relevant legal frameworks.

158. A case involves a pediatric donor (age 3) where the only viable organs are both kidneys. One is allocated to a pediatric recipient, the other to an adult recipient. Walk through the pediatric priority provisions across kidney allocation policy, the size-matching considerations that policy defers to clinical judgment, and the logistics of coordinating simultaneous recovery for two different-sized recipients.

159. An OPO completes a successful multi-organ recovery. Three weeks later, one transplant center reports a positive culture from the preservation fluid, and another center reports an unexpected recipient infection. Walk through the investigation and reporting cascade — Policy 15 obligations, the inter-center communication requirements, and how the OPO coordinates the response across multiple transplant programs.

160. A coordinator is managing their first solo overnight shift and receives three simultaneous referrals. One is a clear donor candidate, one is borderline, and one is likely not going to meet criteria. Walk through the triage framework, the policy-driven evaluation steps for each, and the resource management decisions the coordinator must make — identifying where policy guides the process and where judgment takes over.
